

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 13 February 2021

Situation Report No. 232 - Kingdom of Bahrain
14th of February, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	107,838,255	2,373,398	5,976,060	139,129
New	1,252,117 in 3 days	38,624 in 3 days	77,226 in 3 days	1,052 in 3 days


Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	112,102	104,487	398	7,217	61	2,886,600
New	2,498 in 3 days	1,762 in 3 days	7 in 3 days	-	-	39,943 in 3 days

HIGHLIGHTS

- The mortality were: 6 Bahraini citizens (4 female (59,61, 61 and 76 years old) and 2 male (68 and 68 years old)), and 67 years old female expatriates.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 13 February 2021 is 242,260.
- MOH indicated that most recent active COVID-19 cases are of a variant strain, demanding increased public vigilance.
- Bahrain witnessed an unprecedented surge in COVID-19 cases with the country recording the highest number of infections per million people amongst the GCC in February 2021.
- MOH called on people wishing to take the Russian Sputnik V vaccine to register via the ministry's website healthaert.gov.bh or through BeAware Bahrain application.
- Fifteen people have been jailed for up to six months for gathering illegally and breaching COVID-19 public health protocols.
- Five individuals infected 52 others, including family members and colleagues, with COVID-19 over last week.
- Eleven people are standing trial in connection with an illegal gathering and breaching COVID-19 protocols during religious processions.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
- WHO: COVID-19: Occupational health and safety for health workers; see link below.
- WHO: Weekly operational update on COVID-19 - 13 February 2021; see link below.


Number of New Cases




IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200813-weekly-epi-update-1.pdf?sfvrsn=b6449a76_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news/item/09-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2s4b5dR>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: [https://www.who.int/publications/m/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/m/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assays: <https://bit.ly/2H0YjF>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J2DwWV>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/m/item/97892400117467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/10665337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: <https://www.who.int/publications/m/item/WHO-2019-nCoV-EU-19-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/m/item/WHO-2019-nCoV-Risk-based_International_Travel_Assessment_tool-2020.1
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/m/item/9789240108440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/m/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/m/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: [https://www.who.int/publications/m/item/background-document-on-mrna-vaccine-bnt162b2-\(pfizer-biotech\)-against-covid-19](https://www.who.int/publications/m/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biotech)-against-covid-19)
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-eficacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/news/item/11-06-2020-online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript-1-february-2021>
- WHO: Contact tracing in the context of COVID-19: <https://www.who.int/publications/m/item/contact-tracing-in-the-context-of-covid-19>
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: [https://www.who.int/publications/m/item/background-document-on-the-mrna-1273-vaccine-\(moderna\)-against-covid-19](https://www.who.int/publications/m/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19)
- WHO: COVID-19: Occupational health and safety for health workers: https://www.who.int/publications/m/item/WHO-2019-nCoV-OCW_Advice-2021.1
- WHO: Weekly operational update on COVID-19 - 13 February 2021: <https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-13-february-2021>

Total Number of Cases



Number of New Deaths



IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh